Clinical Outcomes of First-Time and Redo Mitral Valve Replacement Using MITRIS RESILIA Bioprosthesis

Background: The MITRIS RESILIA bioprosthetic valve incorporates anticalcification technology and is designed to facilitate implantation in fragile mitral annuli. However, clinical data on its safety and hemodynamic performance remain limited. Methods: We conducted a retrospective multicenter study of 140 patients (mean age, 75 ± 8 years; 44% male) who underwent first-time (n = 100) or redo (n = 40) mitral valve replacement (MVR) with a MITRIS RESILIA valve between 2021 and 2022. The primary indication for first-time MVR was mitral regurgitation, followed by mitral stenosis, whereas that for redo MVR was prosthetic valve dysfunction, followed by failed repair. The mean follow-up duration was 36 ± 14 months (415 patient-years). Results: < .001). Conclusions: First-time and redo MVR with the MITRIS RESILIA valve was associated with low perioperative mortality, favorable safety, and durable hemodynamic performance. These findings support its use across a broad spectrum of mitral valve diseases.